Adequacy of nutritional support using computed tomography (CT) in patients with head and neck cancer (HNC) during chemo-radiotherapy (CRT).


Journal

European journal of clinical nutrition
ISSN: 1476-5640
Titre abrégé: Eur J Clin Nutr
Pays: England
ID NLM: 8804070

Informations de publication

Date de publication:
10 2021
Historique:
received: 06 03 2020
accepted: 12 01 2021
revised: 04 01 2021
pubmed: 12 2 2021
medline: 31 1 2023
entrez: 11 2 2021
Statut: ppublish

Résumé

We assessed forty HNC patients receiving treatment with curative intent. Specific quantitative muscle and fat changes were evaluated using CT. Nutrition support was provided according to ESPEN guidelines, with adjusted body weight (ABW) in overweight/obese patients used to define their nutritional targets. Linear regression models were used to evaluate clinical predictors of tissue loss. Mean overall losses were body weight (-10.5%), and CT-defined muscle (-8.4%) and fat mass (-24.8%), p < 0.001. A subset of 20 patients had high muscle loss (-14.7%) with concurrent negative energy balance as reflected by considerable fat loss (-29.7%); those tended to have higher baseline body mass index (26.2 vs. 23.3 kg/m

Identifiants

pubmed: 33568807
doi: 10.1038/s41430-021-00863-z
pii: 10.1038/s41430-021-00863-z
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1515-1519

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.

Références

Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58–67.
doi: 10.1016/j.ejca.2015.12.030
Kazemi-Bajestani SMR, Becher H, Butts C, Basappa NS, Smylie M, Joy AA, et al. Rapid atrophy of cardiac left ventricular mass in patients with non-small cell carcinoma of the lung. J Cachexia Sarcopenia Muscle. 2019. https://doi.org/10.1002/jcsm.12451 .
Krenitsky J. Adjusted body weight, pro: evidence to support the use of adjusted body weight in calculating calorie requirements. Nutr Clin Pr. 2005;20:468–73.
doi: 10.1177/0115426505020004468
Tao W, Lagergren J. Clinical management of obese patients with cancer. Nat Rev Clin Oncol. 2013;10:519–33.
doi: 10.1038/nrclinonc.2013.120
ICO-ICS Praxi para el tratamiento médico y con irradiación del cáncer de orofaringe, hipofaringe, laringe y nasolaringe. http://ico.gencat.cat/web/.content/minisite/ico/professionals/documents/arxius/ICO-ICS_cabezaycuello_2017_DEFINITIVA.pdf .
U.S Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). 2017. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf .
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.
doi: 10.1093/jnci/92.3.205
Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge M-P, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol. 2004;97:2333–8.
doi: 10.1152/japplphysiol.00744.2004
Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629–35.
doi: 10.1016/S1470-2045(08)70153-0
Ireton-Jones C. Adjusted body weight, con: why adjust body weight in energy-expenditure calculations? Nutr Clin Pr. 2005;20:474–9.
doi: 10.1177/0115426505020004474

Auteurs

Lorena Arribas (L)

Clinical Nutrition Unit, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain. larribas@iconcologia.net.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. larribas@iconcologia.net.
Head and Neck Cancer Unit, Bellvitge University Hospital, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain. larribas@iconcologia.net.
University of Barcelona, Barcelona, Spain. larribas@iconcologia.net.

Aida Sabaté-Llobera (A)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Nuclear Medicine, PET Unit-IDI, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.

Miren Taberna (M)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Head and Neck Cancer Unit, Bellvitge University Hospital, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
Medical Oncology Department, Catalan Institute of Oncology (ICO), ONCOBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

Natalia Pallarés (N)

Unitat de Bioestadística (UBiDi), Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.

Alicia Narro Marin (A)

Medical Oncology Deparment, Alava University Hospital, Vitoria, Spain.

Nuria Virgili (N)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
University of Barcelona, Barcelona, Spain.
Nutrition and Dietetics Unit, Endocrinology and Nutrition Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.

Laura Hurtós (L)

Clinical Nutrition Unit, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Inmaculada Peiró (I)

Clinical Nutrition Unit, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Esther Vilajosana (E)

Head and Neck Cancer Unit, Bellvitge University Hospital, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
Medical Oncology Department, Catalan Institute of Oncology (ICO), ONCOBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

Alicia Lozano (A)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Head and Neck Cancer Unit, Bellvitge University Hospital, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
Radiation Oncology Department, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.

Vickie Baracos (V)

Division of Palliative Care Medicine, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.

Ricard Mesia (R)

Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Head and Neck Cancer Unit, Bellvitge University Hospital, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
Medical Oncology Department, Catalan Institute of Oncology (ICO)-Badalona, B-ARGO group, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH